CoQ10 in Patients with Nonalcoholic Fatty Liver Disease posted on September 4, 2015 cirrhosiscoenzme Q 10fatty liver disease Share this Post Share on Twitter Share on Facebook Share on Google Plus Non-alcoholic fatty liver disease is the most common cause of chronic liver injury. After 4 weeks of CoQ10 supplementation, waist circumference and serum AST concentrations were significantly decreased as compared to the placebo-treated group. The study showed a potential for CoQ10 therapy in improving serveral anthropometric and biochemical variables in non-alcoholic fatty liver disease. Longer studies with higher doses of CoQ10 are required to further evaluate this potential benefit. Here is the link to the entire article: Oral Coenzyme Q10 Supplementation Improves Various Anthropometric and Biochemical Variables in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) God bless you and to your good health! Joyce Gibb MS, CRNP Ask The Pharmacist Group, LLC Coenzyme Q 10 Softgel 100 mg (60) $35.99 Add to cart No ratings. Coenzyme Q 10 Softgel 200 mg (60) $53.99 Add to cart No ratings.